The ATR inhibitor berzosertib, usually well-tolerated as a single-agent therapy, has shown an increased prevalence of adverse events and hematological toxicities, including anemia, nausea, and neutropenia, when combined with carboplatin56, gemcitabine57,58, or topotecan59 in early-phase clinical trials. The gene discussed is ATR; the disease is anemia.